Tracheobronchial Airway Necrosis: An Atypical Presentation of Recurrent Osteosarcoma

No abstract available
Source: Journal of Bronchology and Interventional Pulmonology - Category: Respiratory Medicine Tags: Images in Interventional Pulmonology Source Type: research

Related Links:

miR‑185 regulates the growth of osteosarcoma cells via targeting Hexokinase 2. Mol Med Rep. 2019 Jul 25;: Authors: Liu C, Cai L, Li H Abstract MicroRNAs (miRNAs) have been proposed as potential prognostic and diagnostic biomarkers in numerous types of cancer, including osteosarcoma (OS), which is the most common bone malignancy. The present study revealed that the expression of miR‑185 was downregulated in OS tissues and cells. Overexpression of miR‑185 significantly suppressed the proliferation and migration of OS cells. To further investigate the functional roles of miR‑185 in OS, the downstr...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Authors: Zeng X, Wang S, Gui P, Wu H, Li Z Abstract Annexin A3 (ANXA3) is highly expressed in different types of cancers, but the impact of ANXA3 in bone tumors is still not clear. In the present study, the expression of ANXA3 in osteosarcoma cells was first confirmed by cellular immunofluorescence. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blot analysis were used to detect the expression of ANXA3 in osteoblasts in the osteosarcoma cell lines U2OS and HOS. Furthermore, small interfering (si)‑RNA were transfected into U2OS and HOS cells via a liposome‑mediated method....
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Authors: Wu J, Zhang C, Chen L Abstract Osteosarcoma, a highly aggressive cancer, can rapidly metastasize to distant organs such as lung, liver, brain. Despite much progress in the therapeutic regime has been made, the prognosis of osteosarcoma remains poor. In present study, microRNA-511 (miR-511) is lowly expressed in osteosarcoma cells, including MG63, U-2 OS, Saos-2 cells, while mitogen activated protein kinase1 (MAPK1) is highly expressed in osteosarcoma cells. Interestingly, MAPK1 might be a target of miR-511. We found that overexpression of miR-511 by miR-511 mimic transfection may result to low expression o...
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
AbstractPurpose of ReviewOsteosarcoma (OS) is the most common cancer of bone, yet is classified as a rare cancer. Treatment and outcomes for OS have not substantively changed in several decades. While the decoding of the OS genome greatly advanced the understanding of the mutational landscape of OS, immediately actionable therapeutic targets were not apparent. Here we describe recent preclinical models that can be leveraged to identify, test, and prioritize therapeutic candidates.Recent FindingsThe generation of multiple high fidelity murine models of OS, the spontaneous disease that arises in pet dogs, and the establishme...
Source: Current Osteoporosis Reports - Category: Orthopaedics Source Type: research
In conclusion, TTN-AS1 functions as a competing endogenous RNA targeting miR-376a and increases the malignancy of OS cells in vitro and in vivo by upregulating DKK1. PMID: 31525734 [PubMed - as supplied by publisher]
Source: Aging - Category: Biomedical Science Authors: Tags: Aging (Albany NY) Source Type: research
Valosin-containing protein promotes metastasis of osteosarcoma through autophagy induction and anoikis inhibition via the ERK/NF-κβ/beclin-1 signaling pathway. Oncol Lett. 2019 Oct;18(4):3823-3829 Authors: Long XH, Zhou YF, Lan M, Huang SH, Li Liu Z, Shu Y Abstract Valosin-containing protein (VCP) promotes the development of metastasis in osteosarcoma (OS) via the PI3K/Akt signaling pathway. However, inhibition of the PI3K/Akt pathway does not completely reverse VCP-mediated invasion and migration of OS, suggesting that VCP-mediated OS invasion and migration involves additional mechanisms. I...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Publication date: Available online 13 September 2019Source: Saudi Journal of Biological SciencesAuthor(s): Shiqiang Fang, Hainan Yin, Zhen Song, Ruixin Li, Xuesheng Xie, Zengquan GuAbstractBone tumor is a rare heterogeneous malignancy. Osteosarcoma is the most common bone tumor with no apparent underlying pathogenesis, and its peak incidence often occurs during puberty. The intensive application of chemotherapy rarely alters the poor prognosis of the patients in advanced stage. Despite intensive chemotherapy in clinical practice, patients still suffer from the poor prognosis, or even progression of bone tumor. We identifie...
Source: Saudi Journal of Biological Sciences - Category: Biology Source Type: research
In this study, we investigated the effect of RRAS2 on osteosarcoma progression and its underlying mechanism. The gene expression level and prognostic power of RRAS2 in osteosarcoma were first investigated using the data from the Gene Expression Omnibus database. Then RNA interference was performed to silence the expression of RRAS2 in osteosarcoma cells. Quantitative real-time-PCR and western blot were used to examine the gene and protein expressions of RRAS2 in osteosarcoma cells. In-vitro cancer proliferation and migration were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolum bromide solution and wound-h...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Preclinical Reports Source Type: research
Osteosarcoma is the most common type of bone malignancies with a poor prognosis. In recent years, targeted therapy has shown great potential in the treatment of osteosarcoma, and more effective therapeutic targets for this disease need to be developed. APLNR is a seven transmembrane G-protein-coupled receptor expressed widely in multiple tissues. As has been reported, APLNR is involved in various physiological and pathological processes. Although APLNR plays a role in the development and progression of multiple tumors, the potential role of APLNR in osteosarcoma, a highly malignant tumor, remains unclear. Here, we reported...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Preclinical Reports Source Type: research
Current therapies fail to cure over a third of osteosarcoma patients and around three quarters of those with metastatic disease. “Smac mimetics” (also known as “IAP antagonists”) are a new class of anti-cancer...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
More News: Bone Cancers | Osteosarcoma